ExploreWatchlistsPricing
  1. JP-listed companies
  2. SEIKAGAKU CORPORATION
  3. Financials
  4. Total non-current assets

SEIKAGAKU CORPORATION (4548)

Market cap
¥42.8B
P/E ratio
45.7x
Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal non-current assets (Million JPY)YoY (%)
Mar 31, 202544,241+9.92%
Mar 31, 202440,248+39.19%
Mar 31, 202328,915+8.63%
Mar 31, 202226,618+0.99%
Mar 31, 202126,357-6.05%
Mar 31, 202028,053-38.81%
Mar 31, 201945,848-14.79%
Mar 31, 201853,806+3.75%
Mar 31, 201751,861+5.95%
Mar 31, 201648,949-4.11%
Mar 31, 201551,045

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat